Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent

by You, M.-L, Chen, Y.-J, Chong, Q.-Y, Wu, M.-M, Pandey, V, Chen, R.-M, Liu, L, Ma, L, Wu, Z.-S, Zhu, T, Lobie, P.E
Published 2020

Inhibition of TFF3 enhances sensitivity—and overcomes acquired resistance—to doxorubicin in estrogen receptor-positive mammary carcinoma

by Poh, H.M., Chiou, Y.S., Chong, Q.Y., Chen, R.-M., Rangappa, K.S., Ma, L., Zhu, T., Kumar, A.P., Pandey, V., Basappa, Lee, S.-C., Lobie, P.E.
Published 2021

Pharmacological inhibition of TFF3 enhances sensitivity of CMS4 colorectal carcinoma to 5-fluorouracil through inhibition of p44/42 MAPK

by Chen, R.-M., Chiou, Y.-S., Chong, Q.-Y., Poh, H.-M., Tan, T.-Z., Zhang, M.-Y., Ma, L., Zhu, T., Pandey, V., Salundi, B., Prem Kumar, A., Lobie, P.E.
Published 2021

A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma

by Zhang, M., Wang, B., Chong, Q.-Y., Pandey, V., Guo, Z., Chen, R.-M., Wang, L., Wang, Y., Ma, L., Kumar, A.P., Zhu, T., Wu, Z.-S., Yin, Z., Basappa, Goh, B.-C., Lobie, P.E.
Published 2021